David Wheeler talks about the findings of the FIGARO trial, the use of finerenone in people with type 2 diabetes, and how this may fit with SGLT2 inhibitors (7:22).
David Wheeler talks about the findings of the FIGARO trial, the use of finerenone in people with type 2 diabetes, and how this may fit with SGLT2 inhibitors (7:22).
Don’t fall behind!
Get the latest headlines – in your specialties of choice – delivered straight to your inbox.
medwireNews Bureau Chief
© 2023 Springer Healthcare Limited.
Part of the Springer Nature Group.
